quinocarcin and Lung-Neoplasms

Quinocarmycin monocitrate is a novel antitumor antibiotic isolated from Streptomyces melanovinaceus. We have utilized a human tumor clonogenic assay to test the antitumor activity of this drug against carcinoma of the lung and to compare its activity with those of mitomycin C or cisplatin, which are components of the clinically effective regimens in therapy for this disease. The overall in vitro response rate (defined as less than 50% survival of tumor colony forming units) for quinocarmycin at 0.1 and 1.0 microgram/ml continuous exposure was 42% and 72%, respectively, which was superior to that of other drugs. Quinocarmycin and other antitumor drugs do not have identical spectra of antitumor activities in vitro, suggesting that this compound with good in vitro activity should be further developed for clinical trials.

Topics: Adenocarcinoma; Antibiotics, Antineoplastic; Colony-Forming Units Assay; Drug Resistance; Drug Screening Assays, Antitumor; Humans; Isoquinolines; Lung Neoplasms; Tumor Stem Cell Assay

The human tumor colony assay was used to evaluate the effect of a new chemotherapeutic agent (KW2152) on colony inhibition of four non-small cell lung cancer cell lines and a mouse cell line. With continuous exposure experiments, KW2152 induced greater than or equal to 70% colony inhibition of PC-7 (human adenocarcinoma), PC-10 (human squamous cell) and PC-13 (human large cell) at a drug concentration of 10 mcg/ml. In one hour exposure experiments, KW2152 caused a significant reduction in colony formation (less than or equal to 30% of control) only at the highest concentration tested (100 mcg/ml). KW2152 showed significant in vitro activity against human non-small cell lung cancer cell lines. Due to these promising results, it was suggested that KW2152 should be evaluated in clinical trials.

Topics: Antineoplastic Agents; Cell Line; Humans; Isoquinolines; Lung Neoplasms; Tumor Stem Cell Assay